Lymphoproliferative Disorders clinical trials at UCSF

4 in progress, 2 open to eligible people

Lymphoproliferative disorders are diseases where too many white blood cells grow. UCSF is testing a drug combo, nanatinostat and valganciclovir, on people with a certain type of this disorder. This is because the disorder is linked to the Epstein-Barr Virus.

Showing trials for

  • Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

    open to eligible people ages 18 years and up

    A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

    San Francisco, California and other locations

  • Project: Every Child for Younger Patients With Cancer

    open to eligible people ages up to 25 years

    This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

    Oakland, California and other locations

  • Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

    Sorry, in progress, not accepting new patients

    This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. LMP-specific T-cells are special immune system cells trained to recognize proteins found on post-transplant lymphoproliferative disorder tumor cells if they are infected with Epstein-Barr virus. Giving rituximab and LMP-specific T-cells may work better in treating pediatric organ recipients with post-transplant lymphoproliferative disorder than rituximab alone.

    San Francisco, California and other locations

  • Registry for People With T-cell Lymphoma

    Sorry, not currently recruiting here

    The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

    San Francisco, California and other locations

Our lead scientists for Lymphoproliferative Disorders research studies include .

Last updated: